COLL Rule 144 Notice: 16,389 Common Shares Proposed Sale on 08/18/2025
Rhea-AI Filing Summary
Form 144 notice for Collegium Pharmaceutical, Inc. (COLL): An insider filed a proposed sale of 16,389 common shares to be brokered through Fidelity Brokerage Services LLC on 08/18/2025 with an aggregate market value of $626,170.29. The filing reports 31,502,127 shares outstanding and lists the exchange as NASDAQ. The securities reported were acquired under an option granted on 02/05/2020 and are noted as acquired on 08/18/2025, with payment indicated as cash. The filing also discloses a prior sale by Scott Dreyer of 4,861 shares on 08/13/2025 for gross proceeds of $184,880.84. The notice includes the standard representation that the seller does not possess undisclosed material adverse information.
Positive
- None.
Negative
- None.
Insights
TL;DR: A Rule 144 filing documents a scheduled sale of 16,389 common shares (insider option exercise) with modest absolute value relative to market cap.
The filing shows an insider intends to sell shares acquired via an option exercise and executed through Fidelity on 08/18/2025. The disclosed aggregate market value is $626,170.29 against 31,502,127 shares outstanding, indicating the sale represents a small fraction of total shares. A recent sale of 4,861 shares on 08/13/2025 for $184,880.84 is also reported. From a securities-transaction perspective this is a routine Rule 144 notice documenting compliance with resale conditions rather than signaling a material corporate development.
TL;DR: Filing documents compliance with Rule 144 for disposition of option-derived shares; disclosure is procedural and non-material on its face.
The notice identifies the nature of acquisition as an option grant dated 02/05/2020 with acquisition and intended sale dated 08/18/2025 and cash payment. It includes the statutory attestation about material non-public information. There are no indications of unusual trading patterns or coordinated large disposals in the filing. Absent further context on holding concentrations or recent executive changes, this filing appears to be a standard compliance disclosure.